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Abstract
Ethanolamine phosphoglycerol (EPG) represents a protein modification that so far has only been found in eukaryotic
elongation factor 1A (eEF1A). In mammals and plants, EPG is covalently attached to two conserved glutamate residues
located in domains II and III of eEF1A. In contrast, Trypanosoma brucei eEF1A contains a single EPG attached to Glu362 in
domain III. The sequence and/or structural requirements for covalent linkage of EPG to eEF1A have not been determined for
any organism. Using a combination of biosynthetic labelling of parasites with tritiated ethanolamine and mass spectrometry
analyses, we demonstrate that replacement of Glu362 in T. brucei eEF1A by site-directed mutagenesis prevents EPG
attachment, whereas single or multiple amino acid substitutions around the attachment site are not critical. In addition, by
expressing a series of eEF1A deletion mutants in T. brucei procyclic forms, we demonstrate that a peptide consisting of 80
amino acids of domain III of eEF1A is sufficient for EPG attachment to occur. Furthermore, EPG addition also occurs if
domain III of eEF1A is fused to a soluble reporter protein. To our knowledge, this is the first report addressing amino acid
sequence, or structure, requirements for EPG modification of eEF1A in any organism. Using T. brucei as a model organism,
we show that amino acid substitutions around the modification site are not critical for EPG attachment and that a truncated
version of domain III of eEF1A is sufficient to mediate EPG addition.
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Introduction
Eukaryotic elongation factor 1A (eEF1A) is one of the most
abundant cytosolic proteins in all eukaryotic cells. It represents an
essential component during (poly-) peptide chain elongation by
binding aminoacyl-tRNAs in a GTP-dependent reaction to the
acceptor site of ribosomes. After codon-anticodon match between
the aminoacylated tRNA and the ribosomal acceptor site followed
by GTP hydrolysis to GDP, eEF1A dissociates from the ribosome
in its GDP-bound form and interacts with nucleotide exchange
factor eEF1Ba, which replaces GDP by GTP to reactivate eEF1A
(reviewed by [1]). Crystal structures of eEF1A in complex with
components of eEF1B show that yeast eEF1A consists of three
clearly distinct domains [2,3]. Domain I harbors the GTP/GDP
binding site, while binding of eEF1Ba occurs to both domains I
and II [2,4]. In addition, domain II also contains the binding site
for aminoacyl-tRNAs [5–7], whereas in yeast domain III
represents the binding site for elongation factor 3 (eEF3) [8].
Apart from its pivotal role during polypeptide synthesis, eEF1A
is involved in many other cellular processes. Most notably, eEF1A
binds to cytoskeletal components and modulates their interactions
[9–11], is involved in signal transduction events [12] and mediates
nuclear export of proteins [13] and mitochondrial tRNA import
[14]. Interactions of eEF1A with components of the cytoskeleton,
which occur independent of its translation elongation function,
have been assigned to domains II and III [15,16]. Such non-
conventional roles for eEF1A may not be surprising since eEF1A
amounts to 1–3% of total cytosolic protein [17] and, thus, is
present in excess compared to its ligands in peptide synthesis.
Since eEF1A is one of the most highly conserved proteins between
eukaryotic species, it likely adopts a similar tertiary structure in all
eukaryotes, as revealed by programs to predict the three-
dimensional structures of proteins. Thus, the sites of interaction
with its ligands are likely conserved in many other organisms as
well.
The biological activity and cellular distribution of a given
protein is often modulated by covalent modifications of amino acid
side chains. Several protein modifications, such as phosphorylation
[18,19], lysine methylation [20,21], and C-terminal methyl-
esterification [22], have been reported to affect the activity of
eEF1A during peptide synthesis in several species, yet their precise
functions remain unknown (reviewed by [23]). In addition,
mammalian and plant eEF1A is modified by ethanolamine
phosphoglycerol (EPG) moieties attached to two conserved
glutamic acid residues in domains II and III [21,24–26]. The
function of this modification, which so far has not been reported in
any other protein except eEF1A, is completely unknown. Very
recently, we have shown that eEF1A of the ancient eukaryote,
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Trypanosoma brucei, is also modified with EPG, however, in contrast
to mammalian and plant eEF1A, T. brucei eEF1A contains a single
EPG modification only. In addition, we showed that the
phospholipid phosphatidylethanolamine (PE) represents the bio-
synthetic precursor of EPG in T. brucei [27]. The enzymes involved
in EPG attachment to eEF1A, or the amino acid sequence or
structure requirements for EPG modification of eEF1A, have not
been characterized. Interestingly, Saccharomyces cerevisiae represents
the only eukaryote so far where eEF1A has been reported not to
be modified with EPG [28].
The present study was aimed at identifying sequence, or
structure, motifs in T. brucei eEF1A necessary for EPG addition. By
replacing (conserved) amino acids at, or around, the EPG
modification site and by deleting individual domains of eEF1A
in T. brucei, we found that attachment of EPG is strictly dependent
on glutamate as the acceptor site and that (part of) domain III of
eEF1A is sufficient to confer EPG modification, even if this
domain is attached to a reporter protein.
Methods
Materials
Unless otherwise specified, all reagents were of analytical grade
and were from Merck (Darmstadt, Germany), Sigma-Aldrich
(Buchs, Switzerland) or ICN Biomedicals (Ta¨gerig, Switzerland).
DNA polymerase was obtained from Qiagen (Hombrechtikon,
Switzerland). All restriction enzymes were purchased from Roche
Diagnostics (Rotkreuz, Switzerland) or New England Biolabs
(Ipswich, MA). [1-3H]ethan-1-ol-2-amine hydrochloride ([3H]Etn,
60 Ci mmol21) was purchased from American Radiolabeled
Chemicals Inc. (St. Louis, MO). Kodak MBX films were obtained
from Kodak SA (Lausanne, Switzerland).
Cell Culture and Transfection
T. brucei Dprocyclin#1 (EP/GPEET null mutant [29]), and the
derived procyclic cell lines were cultured at 27uC in DTM [30]
supplemented with 15% heat-inactivated FBS (Invitrogen, Basel,
Switzerland). Trypanosomes (16108 cells) were harvested at 0.5–
0.86107 cells ml21 and stably transfected by electroporation with
10–15 mg of linearized plasmid DNA. Electroporation was
performed with one pulse (1.5 kV charging voltage, 2.5 kV
resistance, 25 mF capacitance timing, and 186 V resistance timing)
using the BTX Electroporation 600 system (Axon Lab, Baden,
Switzerland) and 0.2 cm pulse cuvette (Bio-Rad, Reinach,
Switzerland). After 24 h of culture, transfectants were selected
for antibiotic resistance by addition of 10 mg ml21 blasticidin S
HCl (Invitrogen) to the culture medium. The transfected cells were
not cloned.
Generation of Expression Vectors and Site-Directed
Mutagenesis
All plasmids containing hemagglutinin-tagged eEF1A (HA-
eEF1A, Table S1) were derived from the trypanosome expression
vector pCorleone [31]. The open reading frame of T. brucei eEF1A
(GeneDB Tb10.70.5670), or parts of it, were amplified from T.
brucei genomic DNA using appropriate primer pairs (Table S2).
PCR products with flanking HindIII and BamHI restriction sites
were subcloned into the pCRH2.1-TOPOH vector (Invitrogen)
following the manufacturer’s instructions and cloned between the
HindIII and BamHI sites of pCorleone. Site-specific mutations of
HA-eEF1A were introduced into the parental vector pE-
GhaEF(12449) (Table S1) using the QuikChangeH Site-Directed
Mutagenesis kit (Stratagene, Basel, Switzerland) and the appro-
priate primers (Table S3). To generate fusion proteins containing
domain III of T. brucei eEF1A linked to Alba 1 (HA-Alba-III) or
PTP (PTP-III), the PCR product corresponding to amino acids
315–449 of eEF1A was subcloned between the EcoRI and BamHI
sites of pBluescript, resulting in pBS(3152449). The open reading
frame of Alba 1 (GeneDB, Tb11.02.2040) was amplified from T.
brucei genomic DNA, and a PTP-tag was generated using plasmid
pN-PURO-PTP as template (GenBank, DQ172901; Schimanski,
2005) and the appropriate primers (Table S2). Resulting PCR
products were inserted between the HindIII and EcoRI sites of
pBS(3152449). The internal BamHI restriction site in the PTP
sequence was removed by site directed mutagenesis as described
above (see Table S2 for primers). The resulting cassettes HA-Alba-
III and PTP-III were cloned between the HindIII and BamHI sites
of pCorleone, resulting in plasmids pEGhaAlba(3152449) and
pEGptp(3152449) (Table S1). All DNA sequences were verified by
sequencing (Microsynth AG, Balgach, Switzerland). Prior to
transfection into T. brucei Dprocyclin#1, the vectors were
linearized with NotI and SalI.
In Vivo Labeling, Extraction and Immunoprecipitation
Trypanosomes during exponential growth (0.5–0.86107 cells
ml21) were labeled with 1 mCi ml21 [3H]Etn for 18 h [32,27].
Subsequently, parasites were harvested and washed twice with ice-
cold TBS (10 mM Tris/HCl, pH 7.4, 144 mM NaCl) to remove
non-incorporated label. Proteins from 26108 cells were extracted
with 300 ml of lysis buffer (50 mM Tris, pH 7.5; 150 mM NaCl;
0.1% (v/v) Nonidet P40), containing complete protease inhibitor
cocktail tablets (Roche Diagnostics), for 15 min on ice. The cell
lysate was homogenized by passing three times through a 27-gauge
needle and cleared by centrifugation at 16,000 g for 30 min. The
supernatant was supplemented with either anti-HA Affinity Matrix
(Roche Diagnostics) or IgG Sepharose 6 Fast Flow matrix (GE
Healthcare, Otelfingen, Switzerland) and incubated on a rotating
device overnight at 4uC. The beads were spun down and washed
three times with lysis buffer. Tagged proteins bound to the matrix
were released by boiling in electrophoresis sample buffer.
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and
Immunoblotting
Glycine-SDS-PAGE was performed under reducing conditions
using 12% polyacrylamide gels [33]. Proteins with predicted
masses smaller than 15 kDa were separated by Tricine-SDS-
PAGE (Scha¨ger, 2006) in the presence of 6 M urea using 16%
polyacrylamide gels. For fluorography of 3H-labeled proteins, gels
were fixed (10% methanol, 7% acetic acid), soaked in Amplify (GE
Healthcare), dried, and exposed to Kodak MBX films at 270uC.
For immunoblotting, proteins were transferred at 2.5 mA/cm2 for
75 min onto polyvinylidene difluoride membranes (Millipore,
Bedford, MA) using a semidry blotting apparatus. The blotted
membranes were blocked overnight with 5% (w/v) milk powder in
TBS containing 0.05% (v/v) Tween 20 and probed with primary
antibody. Mouse monoclonal antibodies against HA (a-HA;
Covance, Berkeley, CA) and eEF1A (a-EF; Upstate, Lake Placid,
NY) were used at a dilution of 1:3000 and 1:5000, respectively.
Primary antibodies and the PTP-tag were detected with secondary
rabbit anti-mouse IgG antibody conjugated to horseradish
peroxidase (Dako, Baar, Switzerland) at a dilution of 1:5000,
followed by enhanced chemiluminescence (Pierce, Lausanne,
Switzerland).
Mass Spectrometry
Immunoprecipitated HA-eEF1A was analyzed by SDS-PAGE
and blotted as described above. After staining with Coomassie
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Brilliant Blue, proteins were cut out and exposed to on-membrane
reductive alkylation and trypsin digestion [34]. The tryptic
peptides were analyzed by liquid chromatography tandem mass
spectrometry (nano-LC-MS/MS) using a Rheos2200 pump,
equipped with GROM-SIL MB6 C8 or Magic-C18 columns
(75 mm, 7 cm), coupled to an LTQ-orbitrap XL mass spectrom-
eter. The peptide-resolving part of the nano-LC gradient was from
5% to 35% acetonitrile in 0.1% formic acid over 20 min at
,400 nl min21. The two most abundant ions were subjected to
collision-induced dissociation (CID) fragmentation using a mass
list comprising all expected 2+/3+ charge states of the modified
and non-modified peptides. CID was triggered first in normal
mode and second with the multistage activation option on when
the prominent neutral loss fragment of 2172 Da was observed as
most abundant ion. CID spectra were recorded in the orbitrap
with resolution set to 7500 at m/z 400. CID spectra were
interpreted by Phenyx software (Genebio SA, Geneva, Switzer-
land) using carboamidomethylation of cysteine as a fixed
modification, and oxidation of methionine and EPG on glutamic
acid as variable modification. All nano-LC-MS/MS chromato-
grams were manually controlled for the presence of the expected
peptides.
Results
Amino Acid Sequence Requirement for EPG Attachment
eEF1A shows a very high amino acid sequence identity over the
entire polypeptide chain between different organisms. Interesting-
ly, however, the residues around the EPG modification site,
Glu362 in T. brucei [27], are less well conserved (Fig. 1). To study
the importance of conserved amino acids within this stretch of the
primary sequence, i.e. between Cys358 and Ile367, for EPG
attachment to eEF1A, we introduced point mutations at, or
around, Glu362 in ectopically expressed, HA-tagged full-length
eEF1A (HA-eEF1A) in T. brucei procyclic forms. Attachment of
EPG to eEF1A was monitored by incubating trypanosomes in
culture with [3H]Etn, which has been used before to label eEF1A
in mammalian cells [24,25], plants [26], and T. brucei [27]. Since
this procedure also results in labeling of abundant GPI-anchored
surface proteins in trypanosomes (see, e.g., [35,36,32,37]), we
chose the T. brucei procyclic cell line, Dprocyclin#1, which lacks
the expression of the major GPI-anchored proteins, EP and
GPEET procyclins [29], for all transfection experiments. Using
this cell line, labeling with [3H]Etn results in a single radioactive
band at 49 kDa after SDS-PAGE and fluorography, allowing easy
identification of wild-type or HA-tagged eEF1A ([27]; see also
below). Expression of the various HA-tagged forms eEF1A had no
effect on growth of the parasites in culture.
Figure 1. Amino acid sequence comparison around the EPG
modification site. The amino acid sequence of T. brucei eEF1A
between residues 347 and 373 is compared to the corresponding eEF1A
sequences from Daucus carota (GenBank, BAA02205) and Mus musculus
(GenBank, NP_034236) using ClustalW. A grey background indicates
amino acid identity between the sequences. The arrows in indicate the
conserved residues at, or around, the EPG modification site of T. brucei
eEF1A (Glu362) that were mutated in this study (E362Q, E362A, E362D,
F360T, A361D, K366S). The box marks the tryptic fragments containing
the EPG modification site (indicated by the asterisk).
doi:10.1371/journal.pone.0009486.g001
Figure 2. Expression of mutated HA-eEF1A and labeling with
[3H]Etn. T. brucei Dprocyclin#1 expressing HA-eEF1A carrying the
point mutations E362Q, E362A or E362D were incubated in the
presence of [3H]Etn for 18 h. HA-eEF1A in the cell lysates (L) and after
immunoprecipitation (IP) were analyzed by SDS-PAGE using 12%
acrylamide gels, followed by immunoblotting using a-HA antibody
(upper panels), or fluorography (lower panels). The lanes contain
material from 16107 parasites, except for the lanes with the
immunoprecipitates in the fluorographs, which contain material
prepared from 1.86108 cell equivalents.
doi:10.1371/journal.pone.0009486.g002
Figure 3. Replacement of a T. brucei eEF1A peptide sequence
by its yeast homologue. (A) The primary sequence of T. brucei eEF1A
between residues 347 and 373 is aligned to the corresponding eEF1A
sequence from S. cerevisiae (GeneDB, YBR118W) using ClustalW (http://
clustalw.genome.ad.jp). A grey background indicates amino acid
identity between the sequences. The arrows indicate the residues that
were sequentially mutated in T. brucei eEF1A (A361D, I363L, E364L,
S365E) to substitute the stretch between Phe360 and K366 (FAEIESK) by
the corresponding S. cerevisiae sequence (FDELLEK). The asterisk
indicates the EPG modification site and the frame marks the tryptic
fragments analyzed by mass spectrometry. (B) T. brucei Dprocyclin#1
expressing HA-eEF1A, containing the yeast sequence FDELLEK instead
of FAEIESK, were incubated with [3H]Etn for 18 h. Proteins in the cell
lysate (L), supernatant (SN), wash solution (W) and immunoprecipitate
(IP) were separated and analyzed by immunoblotting as described in
Fig. 2. The lanes contain material from 16107 parasites, except for the
lanes with the immunoprecipitates in the fluorographs, which contain
material prepared from 1.86108 cell equivalents.
doi:10.1371/journal.pone.0009486.g003
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Immunoblotting experiments showed that HA-eEF1A pro-
teins carrying the point mutations E362Q, E362A and E362D
were expressed in T. brucei procyclic forms and could be
immunoprecipitated using a-HA antibodies (Fig. 2, upper
panels). As expected, replacement of the glutamate residue
representing the EPG attachment site by glutamine (E362Q), or
alanine (E362A), resulted in complete loss of [3H]Etn labeling of
HA-eEF1A (Fig. 2, lower left and middle panels). In addition,
substitution of glutamate by aspartate (E362D) also completely
abolished labeling of HA-eEF1A (Fig. 2, lower right panel),
indicating that the length of the amino acid side chain is critical
for [3H]Etn incorporation into eEF1A. The radioactive bands at
49 kDa in the lysates of the respective experiments represent
endogenous [3H]Etn-labeled eEF1A, demonstrating that uptake
and incorporation of [3H]Etn into wild-type eEF1A was
unaltered in these mutant parasites. To study the importance
of the three conserved amino acids in the vicinity of the EPG
attachment site, Phe360, Ala361 and Lys366, we expressed HA-
eEF1A proteins carrying the point mutations F360T, A361D or
K366S in trypanosomes. The results after incubating parasites
expressing these proteins with [3H]Etn show that the mutations
didn’t prevent labeling of HA-eEF1A with [3H]Etn (results not
shown).
Since the conserved glutamate residue in eEF1A from S.
cerevisiae is not modified with EPG [28], we converted the tryptic
peptide of T. brucei eEF1A, FAEIESK, carrying the EPG
modification site, to the corresponding tryptic peptide from yeast
eEF1A, FDELLEK (Fig. 3A), and studied its potential modifica-
tion in T. brucei. Our results show that replacement of all four
amino acids around the EPG attachment site to mimic the yeast
sequence had no effect on [3H]Etn labeling of HA-eEF1A in T.
brucei (Fig. 3B).
Mass Spectrometry Analysis of EPG Attachment to
Mutated HA-eEF1A
Although incorporation of [3H]Etn into eEF1A is a helpful and
convenient marker for EPG labeling, it provides no information on
the exact site of modification, or if the entire EPG moiety–and not
only ethanolamine (see [38]) – is attached. To obtain this
information, purified (immunoprecipitated) HA-tagged proteins
were reduced, alkylated, digested with trypsin, and analyzed by
nano-LC-MS/MS. All tryptic peptides recovered matched the
deduced amino acid sequence of wild-type T. brucei eEF1A (results
not shown), except for the peptides carrying the point mutations
(see below). HA-tagged wild-type eEF1A revealed a tryptic
fragment with m/z 1020.465 and 510.736, representing the
[M+H]+ and [M+2H]2+ ions of the heptapeptide FAEIESK
(Phe360 to Lys366, 823.420 Da), carrying an EPG moiety with the
predicted mass of 197.045 Da (results not shown; see also Table 1
and [27]). MS/MS analysis of the parental ion at m/z 510.736
identified Glu362 in the sequence of the tryptic peptide
FAE*IESK (with E* indicating EPG-modified glu) as the site of
EPG attachment (Fig. 4A). The ion spectrum showed a major
[M+2H]2+ ion of m/z 424.718 after neutral loss of 172.014 Da due
to elimination of glycerol phosphate, leaving Glu362 modified
with NH–CH=CH2. In contrast, analysis of the HA-eEF1A
E362D mutant revealed a tryptic fragment with m/z 809.404 and
405.206, representing the [M+H]+ and [M+2H]2+ ions of the
unmodified heptapeptide FADIESK (results not shown; see also
Table 1), with MS/MS analysis of the parental ion at m/z 405.206
confirming the absence of EPG (Fig. 4B). Similarly, only the
unmodified tryptic peptides FAQIESK and FAAIESK were
detected in the E362Q and E362A mutants, respectively
(Table 1). In contrast, point mutations at the conserved residues
Ala361 and Lys366 had no effect on EPG attachment to T. brucei
Table 1. Characteristic ions of the tryptic fragments of T. brucei eEF1A proteins detected by mass spectrometry.
Protein Tryptic fragment [M+H]+ [M+H]2+ EPG
Wild-type FAE*IESK/FAEIESK 1020.465/823.420a 510.736/412.214a +
E362Q FAQ*IESK/FAQIESK n.d./822.435 n.d./411.722
E362A FAA*IESK/FAAIESK n.d./765.414 n.d./383.210
E362D FAD*IESK/FADIESK n.d./809.404 n.d./405.206
F360T TAE*IESK/TAEIESK o o
A361D FDE*IESK/FDEIESK 1064.454/867.409 532.731/434.209 +
K366S FAE*IESSIDR/FAEIESSIDR & 1363.613/n.d. 682.313/n.d. +
FAE*IESSIDRR/FAEIESSIDRR 1519.714/n.d. 760.362/n.d. +
A361D/I363L FDE*LESK/FDELESK 1064.444/867.401 532.725/434.204 +
A361D/I363L/E364L FDE*LLSK/FDELLSK 1048.485/851.442 524.745/426.225 +
A361D/I363L/E364L/S365E FDE*LLEK/FDELLEK 1090.491/893.447 545.749/447.228 +
315–394 FAE*IESK/FAEIESK 1020.466/823.432 510.736/412.219 +
348–449 FAE*IESK/FAEIESK 1020.463/823.420 510.736/412.213 +
HA-Alba-III FAE*IESK/FAEIESK 1020.466/823.419 510.736/412.214 +
PTP-III FAE*IESK/FAEIESK 1020.463/n.d. 510.734/412.212 +
Purified T. brucei HA-eEF1A was digested with trypsin and subjected to nano-LC-MS/MS as described in Experimental Procedures. Tryptic fragments containing the site
of potential EPG attachment (marked by the asterisk) with the corresponding [M+H]+and [M+2H]2+ ions are listed.
n.d., not detected
o, no fragments detected
a the relative intensities of the [M+H]+ ions of the EPG-modified (m/z 1020.465) and unmodified (m/z 823.420) tryptic peptides suggest that .95% of wild-type eEF1A is
modified with EPG.
The last column indicates the presence (+) of the EPG modification based on the ion data.
doi:10.1371/journal.pone.0009486.t001
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HA-eEF1A, as demonstrated by detection of the EPG-modified
peptides FDE*IESK, FAE*IESSIDR and FAE*IESSIDRR
(Table 1). For unknown reasons, no TAE*IESK peptide of the
F360T mutant could be detected by MS analysis; however, the
successful introduction of the point mutation in the open
reading frame of HA-eEF1A was confirmed by PCR and DNA-
sequencing. Finally, MS analysis of HA-eEF1A mimicking the
yeast eEF1A sequence around the EPG modification site
showed the presence of the EPG-modified peptide, FDE*LLEK
(Table 1).
MS analysis of all immunoprecipitated HA-eEF1A proteins
showed the presence of trace amounts of the tryptic peptide
FAE*IESK (results not shown), indicating that HA-eEF1A
interacts with endogenous eEF1A. This is consistent with reports
showing that eEF1A in Tetrahymena exists as homodimers and that
dimer formation occurs via domain III [11,39].
Together, these results demonstrate that the attachment of EPG
to eEF1A only occurs if Glu362 is strictly conserved, but is not
affected by substitution of conserved amino acids in the vicinity of
the modification site. Based on these observations, and our failure
to identify an amino consensus sequence in eEF1A that could
mediate EPG attachment, we investigated if a structural domain
may determine EPG modification of eEF1A.
EPG Attachment to eEF1A Deletion Mutants
The predicted three dimensional structure of T. brucei eEF1A
shows three distinct structural domains (Fig. 5A, termed I, II and
III) and closely matches the three dimensional structure of S.
cerevisiae eEF1A as determined by X-ray crystallography [3]. The
Glu362 residue modified by EPG in T. brucei eEF1A is located in a
predicted b-sheet in domain III (Fig. 5A). To determine the
structural requirements for the attachment of EPG to Glu362,
Figure 4. Analysis of EPG attachment by mass spectrometry. Tryptic peptides from T. brucei HA-eEF1A mutants were subjected to nano-LC-
MS/MS and the collision-induced fragmentation spectra of ions m/z 510.736 and 405.206, corresponding to EPG-modified FAE*IESK and unmodified
FADIESK, respectively, are shown. The intensity scale in panel A is set to 12.5% of the most abundant ion of 424.718, which corresponds to the doubly
charged parent ion after neutral loss of glycerol phosphate. The y and b type ions are marked with the corresponding m/z of the singly charged ions
given above or underneath the amino acid sequence.
doi:10.1371/journal.pone.0009486.g004
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several HA-tagged deletion mutants of T. brucei eEF1A were
designed (Fig. 5B) and transfected into T. brucei procyclic forms.
Expression of HA-eEF1A and incorporation of [3H]Etn was
monitored as described for the point mutations. Immunoblotting
experiments using a-HA demonstrate that eEF1A proteins lacking
domain II (construct 1–243/315–449) or domains I + II (construct
315–449), as well as HA-tagged full-length eEF1A (construct 1–
449), were expressed (Fig. 6A). The minor band migrating below
HA-tagged eEF1A lacking domain II likely represents a proteolytic
degradation product of the protein construct. Interestingly, after
incubation of trypanosomes with [3H]Etn, the two truncated
proteins were strongly labeled (Fig. 6B), indicating that domains I
and II are not required for incorporation of [3H]Etn into domain
III of T. brucei eEF1A.
To identify a minimal structural unit of domain III needed
for [3H]Etn incorporation, we generated deletion mutants of
domain III and analyzed their expression and labeling with
[3H]Etn. The results show that the truncated forms of domain
III, after deletion of 33 amino acids at the N-terminus
(construct 348–449) or 55 amino acids at the C-terminus
Figure 5. Tertiary structure of T. brucei eEF1A and design of deletion mutants. (A) Predicted three-dimensional structure of T. brucei eEF1A
using PyMol (http://www.pymol.org). The site of EPG attachment, Glu362, is exposed on the surface of domain III. Domain III is highlighted in colour;
the amino acid sequence common to the minimal structural units showing EPG attachment (residues 348–394) is indicated in red, the flanking N- and
C-terminal stretches (residues 315–347 and 395–449, respectively) are in yellow. (B) Overview of HA-tagged deletion mutants of T. brucei eEF1A. The
numbers indicate the positions of the amino acids in the full length protein. The black boxes represent the HA-tags and the asterisks indicate the EPG
modification site (Glu 362). Predicted molecular masses are indicated in kDa on the right.
doi:10.1371/journal.pone.0009486.g005
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(construct 315–394), were expressed (Fig. 6A) and, in addition,
labeled with [3H]Etn (Fig. 6B). In contrast, no expression was
observed after truncating both the N- and the C-terminus of
domain III, resulting in a peptide fragment consisting of amino
acids 348–394 of eEF1A (results not shown). To confirm the
site of attachment and the structure of the modification, the
deletion mutants were analyzed by nano-LC-MS/MS. The
results showed that the purified (immunoprecipitated) HA-
tagged eEF1A peptides 348-449 and 315–394 were modified at
Glu362 and that the entire EPG structure was present
(Table 1). Together, these results demonstrate that a peptide
consisting of 80 amino acids of domain III of eEF1A is
sufficient for EPG modification in T. brucei.
EPG Attachment to Chimeric Proteins
Having demonstrated that domain III of eEF1A alone is
modified by EPG, we next studied if linking this domain to other
proteins confers EPG modification to the chimeric proteins. For
this purpose, we linked domain III of eEF1A to the small cytosolic
protein, T. brucei Alba 1, or to the tandem affinity purification tag,
PTP [40], resulting in the chimeric proteins HA-Alba-III or PTP-
III with predicted molecular masses of 30 or 33 kDa, respectively.
Immunoblotting experiments showed that both constructs were
expressed in T. brucei procyclic forms (Fig. 7A, B, upper panels)
and incorporated [3H]Etn (Fig. 7A, B, lower panels). Nano-LC-
MS/MS analysis of immunoprecipitated proteins confirmed the
presence of the entire EPG moiety attached to Glu362 of domain
III (Table 1). These data demonstrate that domain III of eEF1A is
modified with EPG as independent structural unit, regardless if it
is expressed as individual polypeptide or attached to other
proteins.
Discussion
Based on the published three-dimensional structure of yeast
eEF1A [3,4] and the high amino acid sequence homology between
eEF1A from different organisms, the EPG modification site in T.
brucei eEF1A, Glu362, is predicted to be on the surface of a b-sheet
in domain III. Using in vivo labeling with [3H]ethanolamine and
mass spectrometric analyses, we now showed that a peptide
consisting of amino acids 315–394 of the primary sequence, which
is located in domain III of eEF1A, is sufficient for EPG attachment
to occur. This was demonstrated by expressing HA-tagged forms
of eEF1A lacking domains I and/or II, or the N- and C-terminal
parts of domain III. Similarly, EPG modification also occurred on
chimeric proteins consisting of domain III of T. brucei eEF1A fused
to soluble reporter proteins, demonstrating that domain III
contains all necessary information to become EPG-modified. In
addition, point mutations of conserved amino acids around the
EPG attachment site didn’t prevent EPG modification, indicating
that a specific primary sequence does not appear to be involved in
EPG attachment. Furthermore, while replacement of Glu362 by
Ala or Gln was expected to block EPG attachment, replacement
by Asp also completely abolished EPG addition, demonstrating
that the enzyme catalyzing attachment of EPG, or its precursor
molecule, is highly specific for Glu at this position and doesn’t
Figure 6. Expression of HA-eEF1A deletion mutants and
labeling with [3H]Etn. T. brucei Dprocyclin#1 expressing full length
HA-eEF1A, or HA-tagged deletion mutants, were incubated in the
presence of [3H]Etn for 18 h. Subsequently, parasites were lysed, and
HA-tagged proteins were immunoprecipitated and analyzed by glycine-
SDS-PAGE (left panels) or Tricine-SDS-PAGE (right panels). HA-eEF1A
was visualized by immunoblotting using a-HA (upper panels), whereas
labeling with [3H]Etn was analyzed by fluorography (lower panels). The
lanes contain material from 16107 parasites, except for the lanes with
the immunoprecipitates in the fluorographs, which contain material
prepared from 1.86108 cell equivalents. The deletion mutants are
marked according to Fig. 5B. Molecular mass markers are indicated in
kDa.
doi:10.1371/journal.pone.0009486.g006
Figure 7. Expression of domain III fusion mutants and labeling
with [3H]Etn. (A), (B), T. brucei Dprocyclin#1 expressing HA-Alba-III
and PTP-III fusion proteins were labeled with [3H]Etn for 18 h. Proteins
in the cell lysates (L), supernatants (SN), wash solutions (W) and
immunoprecipitates (IP) were analyzed by SDS-PAGE using 12%
acrylamide gels. SDS PAGE was followed either by immunoblotting
(upper panels) or fluorography (lower panels). For immunoblotting a-
HA antibody or a-IgG were used to detect HA-Alba-III or PTP-III,
respectively. The lanes contain material from 16107 parasites, except
for the lanes with the immunoprecipitates in the fluorographs, which
contain material prepared from 1.86108 cell equivalents.
doi:10.1371/journal.pone.0009486.g007
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recognize a carboxyl group linked to a shorter amino acid side
chain.
Mammalian and plant eEF1A contain two EPG residues
attached to Glu in domains II and III [24–26]. This is in contrast
to T. brucei, where eEF1A is modified with a single EPG moiety in
domain III only ([27] and this report), despite the fact that the
second potential modification site, Glu289, is strictly conserved
between trypanosomes, mammals and plants. Our results demon-
strate that this residue remains unmodified in T. brucei even if EPG
attachment to Glu362 is prevented by point mutations.
Until today, EPG attachment has only been described in
eEF1A. Two other amino acid side chain modifications show a
similar selectivity for single proteins. In analogy to eEF1A, these
proteins, eukaryotic translation initiation factor 5A (eIF5A) and
elongation factor 2 (eEF2), are also involved in polypeptide
elongation. First, hypusine (Ne-(4-amino-2-hydroxybutyl)-lysine)
represents a post-translationally modified lysine residue in eIF5A
([41]; reviewed by [42]). It has been described in eukaryotes and
archaeabacteria, but is absent from bacteria. Recent reports have
demonstrated that eIF5A associates in a hypusine-dependent way
with actively translating ribosomes, suggesting that eIF5A may
have a role in polypeptide elongation rather than, or in addition
to, translation initiation [43–45]. In addition, the hypusine
modification may be involved in correct localization of eIF5A
within the cytosol [46]. The biosynthetic pathway leading to
hypusine formation has been established (reviewed by [42]).
Furthermore, a minimal structural domain of eIF5A necessary for
hypusine modification has been identified [47].
Second, diphthamide, 2-(3-carboxyamido-3-(trimethylammonio)-
propyl)-histidine represents a post-translationally modified histidine
residue found only in eEF2 ([48]; reviewed by [49]). Similar to
hypusine, diphthamide has been conserved throughout eukaryotic
and Archaea evolution. It represents the target for ADP-ribosylation
by bacterial toxins, rendering eEF2 inactive and causing inhibition of
protein synthesis. However, its physiological role is still unclear, as
several studies have demonstrated that eEF2 function is not directly
dependent on diphthamide formation (reviewed by [49]). More
recently, evidence for a direct role of diphthamide in cell function has
been obtained when yeast strains expressing diphthamide-deficient
eEF2 were shown to have increased -1 frame-shifting [50]. In
addition, diphthamide was demonstrated to protect mutant
mammalian cells from the action of the ribosome-inactivating
protein, ricin [51]. The biosynthetic pathway leading to attachment
of diphthamide to eEF2 has been completely solved in S. cerevisiae
(reviewed by [49]). In contrast to EPG addition to eEF1A, the
conserved amino acid residues around the modification site are
critical for diphthamide formation in eEF2 [50,52].
Similar to hypusine and diphthamide, EPG is absent in bacteria
[25]. However, whereas hypusine and diphthamide seem to be
present in all eukaryotes, EPG was reported to be absent in eEF1A
from S. cerevisiae [28]. In line with this observation, we were unable
to label yeast eEF1A using [3H]ethanolamine in vivo (results not
shown). To test if yeast eEF1A lacks EPG because the biosynthetic
pathway is deficient or if structure or sequence differences in yeast
eEF1A prevent EPG attachment, we tried to express a tagged form
of T. brucei eEF1A in S. cerevisiae, and vice versa. Unfortunately,
despite several attempts we were unable to obtain expression of
HA-tagged T. brucei eEF1A in different yeast strains. In contrast,
HA-tagged eEF1A from S. cerevisiae was readily expressed in T.
brucei procyclic forms, however, it was not modified with
[3H]ethanolamine (results not shown). At present, it is unclear if
yeast eEF1A was not modified in T. brucei because it is not properly
folded. However, our results showing that replacement of the
primary sequence around the EPG attachment site of T. brucei
eEF1A by the yeast sequence didn’t affect EPG attachment in T.
brucei, demonstrate that the different amino acid sequence of yeast
eEF1A per se is not responsible for the lack of EPG modification in
S. cerevisiae.
The pathways involved in EPG attachment to eEF1A, and its
biological functions, are completely unknown. Our observations
that domain III of eEF1A, expressed either as separate entity or
fused to tagged proteins in T. brucei, is modified with EPG suggest
that it may be feasible to identify interaction partners of EPG-
modified eEF1A using tagged domain III to advance the general
knowledge on the synthesis and role of this enigmatic protein
modification using trypanosomes as model system.
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